Follicular Lymphoma

>

Latest News

Behind the FDA Approval of Zanubrutinib and Obinutuzumab in Follicular Lymphoma
Behind the FDA Approval of Zanubrutinib and Obinutuzumab in Follicular Lymphoma

March 8th 2024

Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.

FDA Approves Zanubrutinib and Obinutuzumab in R/R Follicular Lymphoma
FDA Approves Zanubrutinib and Obinutuzumab in R/R Follicular Lymphoma

March 7th 2024

FDA Grants Priority Review to Epcoritamab for R/R Follicular Lymphoma
FDA Grants Priority Review to Epcoritamab for R/R Follicular Lymphoma

February 27th 2024

Tisa-cel Offers Durable Responses in R/R Follicular Lymphoma
Tisa-cel Offers Durable Responses in R/R Follicular Lymphoma

February 16th 2024

Second-Line Liso-cel Shows Promise in High-Risk Relapsed/Refractory FL
Second-Line Liso-cel Shows Promise in High-Risk Relapsed/Refractory FL

January 12th 2024

Video Series
Video Interviews

More News